Some reports support ticagrelor as a potent and reversible P2Y12 inhibitor, while others prefer the use of prasugrel owing to its high potency and lack of interaction with COVID-19 therapies [28,30,31,34,38]. The gene discussed is P2RY12; the disease is COVID-19.